CARL ZEISS MEDITEC ADR 1 (AFXA) — Cash Flow-to-Debt Ratio
CARL ZEISS MEDITEC ADR 1 (AFXA) has a Cash Flow-to-Debt Ratio of 0.11x as of September 2025, meaning its operating cash flow of €144.16 Million could theoretically repay 0% of its total liabilities (€1.28 Billion) in one year. Check CARL ZEISS MEDITEC ADR 1 (AFXA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CARL ZEISS MEDITEC ADR 1 Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for CARL ZEISS MEDITEC ADR 1 across 4 annual periods. Also explore AFXA total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for CARL ZEISS MEDITEC ADR 1 (2022–2025)
Year-by-year debt coverage analysis for CARL ZEISS MEDITEC ADR 1. For market capitalisation and broader financial context, see CARL ZEISS MEDITEC ADR 1 stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | €209.86 Million | €1.28 Billion | ▼ -11.1% |
| 2024 | 0.19x | €247.32 Million | €1.34 Billion | ▼ -36.6% |
| 2023 | 0.29x | €250.86 Million | €860.02 Million | ▲ +22.9% |
| 2022 | 0.24x | €188.20 Million | €792.73 Million | — |